• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

    1/28/25 7:16:42 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNTX alert in real time by email
    Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
    Get the next $RNTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RNTX

    DatePrice TargetRatingAnalyst
    1/28/2025$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $RNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

      1/28/25 7:16:42 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

      Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern TimeAUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medications to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it adjourned, without conducting any business, the 2025 annual meeting of stockholders (the "Annual Meeting") on Tuesday, June 24, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for Company stockholders to vote on all proposals described in Rein's definitive proxy statement filed with the Securities and Exchan

      6/24/25 10:11:00 AM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

      Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas, May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.

      5/27/25 7:00:00 AM ET
      $IQV
      $RNTX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

      Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF) Company recently initiated RENEW Phase 2 trial evaluating the safety, tolerability and efficacy of LTI-03 in IPF AUSTIN, Texas, May 19, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company and its collaborators presented two posters supporting the potential therapeutic effectiveness of LTI-03 in idiopathic pulmonary fibros

      5/19/25 4:51:00 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Aivado Manuel

      4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

      7/23/25 7:42:24 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Von Rickenbach Josef H

      4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

      7/23/25 7:40:12 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Musso Alan A

      4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

      7/23/25 7:38:33 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Rein Therapeutics Inc.

      8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

      7/23/25 4:01:13 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Rein Therapeutics Inc.

      DEFA14A - Rein Therapeutics, Inc. (0001420565) (Filer)

      7/11/25 4:05:58 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Rein Therapeutics Inc.

      8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

      7/11/25 4:01:26 PM ET
      $RNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care